MedTrace Logo

BCG and Plasma Amyloid in Non-Demented Adults

NCT04449926 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 49

Last updated 2021-12-23

No results posted yet for this study

Summary

BCG vaccination, the most widely used vaccination in the world, is used to reduce risk of tuberculosis infection; it is used for other mycobacterial infections as well, benefiting leprosy and Buruli ulcer. BCG has "heterologous" effects that aids in an array of non-mycobacterial and viral infections as well as bladder cancer. It is the heterologous effect, sometimes called the "off-target" effect that may offer benefit in Alzheimer's disease. Population studies and studies of adults receiving BCG show a lessened risk of Alzheimer's disease. The study will see if BCG vaccination will alter a plasma test for amyloid, a biomarker for cerebral amyloid.

Conditions

  • Alzheimer Disease, Late Onset

Interventions

BIOLOGICAL

Bacillus of Calmette and Guerin (BCG)

Prime and boost vaccination

Sponsors & Collaborators

  • Mindful Diagnostics and Therapeutics, LLC

    lead INDUSTRY

Principal Investigators

  • Coad T Dow, M.D. · Mindful Diagnostics and Therapeutics

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
50 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-11-09
Primary Completion
2021-12-04
Completion
2021-12-05
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04449926 on ClinicalTrials.gov